ChemCentre is proud to be attending ACannabis 2025, Australia’s premier medicinal cannabis conference, taking place in Melbourne from 12–13 August.
Angela Downey, Manager of Organic Chemistry, and Chris May, Team Leader of Organic Chemistry, will attend on behalf of ChemCentre to connect with stakeholders across the medicinal cannabis industry and share insights into our unique analytical capabilities.
Hosted annually by the Medicinal Cannabis Industry Australia (MCIA), ACannabis brings together participants from across the medicinal cannabis ecosystem—policy makers, regulators, researchers, healthcare professionals, global leaders, patients, and industry representatives. The program explores innovations in cultivation, manufacturing, compliance, regulation, education, and technology.
Did you know ChemCentre is one of the few laboratories in Australia to offer analytical testing of medicinal cannabis under a Therapeutic Goods Administration (TGA) Manufacturing Licence (MI-2019-LI-04564-1) and Good Manufacturing Practice (GMP) certification (MI-2025-LI-05121-1)?
These certifications enable ChemCentre to conduct highly specialised analysis of medicinal cannabis products in line with Therapeutic Goods Order No. 93 (TGO 93).
Our testing services include:
- Full cannabinoid profile
- Terpenes
- Mycotoxins
- Heavy metals
- Pesticides
- Foreign matter
- ICH Stability testing to support shelf-life determination under various conditions
Many of these analyses are also NATA-accredited, giving manufacturers and distributors confidence in meeting both local and international regulatory requirements.
Robust and reliable testing plays a critical role in ensuring the safety and quality of prescribed medicinal cannabis products, while also supporting the ongoing growth and sustainability of Australia’s medicinal cannabis industry.
While Angela and Chris won’t be presenting this year, they’ll be on the ground and happy to connect to discuss how ChemCentre can support your already growing business or your entry into emerging and established medicinal cannabis markets.
